Curis (CRIS) Expected to Announce Earnings on Monday

Curis (NASDAQ:CRIS) is anticipated to post its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect Curis to post earnings of ($0.4360) per share and revenue of $3.2490 million for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 19, 2026 at 4:30 PM ET.

Curis (NASDAQ:CRIS) last released its quarterly earnings data on Thursday, March 19th. The biotechnology company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The company had revenue of $1.14 million during the quarter, compared to analysts’ expectations of $3.25 million. On average, analysts expect Curis to post $-7 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Curis Stock Performance

Shares of CRIS stock opened at $0.56 on Friday. Curis has a 1 year low of $0.52 and a 1 year high of $3.13. The stock has a fifty day moving average price of $0.95 and a 200 day moving average price of $1.21. The stock has a market cap of $7.63 million, a PE ratio of -0.47 and a beta of 3.02.

Analyst Upgrades and Downgrades

Several research firms have recently commented on CRIS. Wall Street Zen upgraded shares of Curis to a “hold” rating in a research report on Saturday. Weiss Ratings restated a “sell (e+)” rating on shares of Curis in a research report on Wednesday, January 21st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $17.00 price objective on shares of Curis in a research note on Friday, March 20th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $17.00.

Hedge Funds Weigh In On Curis

Several institutional investors and hedge funds have recently modified their holdings of the company. Jane Street Group LLC grew its stake in Curis by 71.8% in the 4th quarter. Jane Street Group LLC now owns 25,323 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 10,586 shares during the period. XTX Topco Ltd acquired a new position in Curis in the 4th quarter valued at $26,000. Squarepoint Ops LLC lifted its stake in shares of Curis by 17.9% during the 3rd quarter. Squarepoint Ops LLC now owns 59,140 shares of the biotechnology company’s stock worth $98,000 after purchasing an additional 8,973 shares during the period. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Curis by 2,883,237.5% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 230,667 shares of the biotechnology company’s stock worth $228,000 after purchasing an additional 230,659 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in shares of Curis by 37.3% during the fourth quarter. Renaissance Technologies LLC now owns 240,917 shares of the biotechnology company’s stock worth $238,000 after purchasing an additional 65,404 shares during the last quarter. Hedge funds and other institutional investors own 29.97% of the company’s stock.

Curis Company Profile

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.